RxDoctor Payments Data

Christopher Riemann, MD

Ophthalmology · Cincinnati, OHNPI 1962491571

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $342,761 of the $462,930 with a category attached, or 74.0%. 36 manufacturers reported payments, led by Haag-streit USA, Inc. at 32.2% of the total. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$462,930in general payments, 2019–2025

Across 481 payments — averaging $962.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haag-streit USA, Inc.$149K
  • Medone Surgical Inc$100K
  • Astellas Pharma US Inc$52K
  • Dutch Ophthalmic Research Center (international) B.v.$37K
  • Alcon$23K
  • W. L. Gore & Associates, Inc.$20K
  • plus $82K from 30 others
$614,990in research payments, 2019–2025

Across 41 payments — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$393K
  • Ocular Therapeutix, Inc.$77K
  • Alimera Sciences, Inc.$47K
  • Novartis$40K
  • Alcon Research LLC$35K
  • ANI Pharmaceuticals, Inc.$23K

What the payments were for

  • Royalty or licence$12,8463%
  • Consulting fees$342,76174%
  • Speaking & faculty fees$71,64515%
  • Travel & lodging$17,7894%
  • Food & beverage$16,5954%
  • Education$1410%
  • Gifts$560%
  • Entertainment$1,0970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Haag-streit USA, Inc.(2 entities)41$149,105
Medone Surgical Inc9$99,829
Astellas Pharma US Inc40$52,279
Dutch Ophthalmic Research Center (international) B.v.9$36,548
Alcon30$23,209
W. L. Gore & Associates, Inc.6$19,607
Alcon Research LLC14$16,019
Novartis16$12,838
ANI Pharmaceuticals, Inc.24$10,044
Genentech, Inc.4$8,219
Bausch & Lomb Americas Inc.19$6,077
Alimera Sciences, Inc.51$6,069
Dutch Ophthalmic, USA8$4,202
Carl Zeiss Meditec, Inc.5$4,085
Carl Zeiss Meditec USA, Inc.4$3,414
AbbVie(2 entities)41$3,115
Regeneron Healthcare Solutions, Inc.51$2,564
Bausch & Lomb, A Division Of Bausch Health US, LLC17$1,871
Genentech USA, Inc.31$992
Apellis Pharmaceuticals, Inc.16$765
Eyepoint US, Inc.15$624
Regeneron3$256
Spark Therapeutics, Inc.3$180
Samsara Vision2$175
Leica Microsystems Inc.3$156
Astellas US LLC1$136
Biogen4$123
Mallinckrodt Hospital Products Inc.2$120
Sandoz4$98
Lombart Brothers, Inc.2$56
AstraZeneca1$43
Astellas Pharma Global Development1$33
Janssen Global Services, LLC1$29
Amgen1$22
Aerie Pharmaceuticals, Inc.1$17
Lumibird Medical Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$462,930 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$4,247,835
Medicare patients
769
Services billed
29,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate375$16,440
CombiganBrimonidine Tartrate/Timolol35$9,980
ProlensaBromfenac Sodium12$4,194
Difluprednate21$2,929
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$2,355
Brimonidine Tartrate80$1,299
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim151$1,101
Atropine Sulfate22$800
Timolol Maleate91$636
MoxifloxacinMoxifloxacin Hcl11$422
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat26$345
Latanoprost35$335
Diclofenac Sodium12$171
Ofloxacin18$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$3,115$9,98035 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$1,871$4,19412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →